What's new in NSAID pharmacotherapy: Oral agents to injectables

Pain Medicine (United States)

Volumn 14, Issue SUPPL1, 2013, Pages

  Atkinson, Timothy J ^a   Fudin, Jeffrey ^a,b,c,d,e   Jahn, Heather Lynne ^a   Kubotera, Natsuki ^f   Rennick, Amanda Leigh ^a   Rhorer, Mary ^a  

^a STRATTON VA MEDICAL CENTER   (United States)

^b American Academy of Pain Management   (United States)

^c ALBANY COLLEGE OF PHARMACY   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

^f PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase Inhibiting Nitric Oxide Donor; Glycoscience; Nano Formulated; NSAID; SI 613

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; DICLOFENAC PLUS MISOPROSTOL; ESOMEPRAZOLE PLUS NAPROXEN; FAMOTIDINE PLUS IBUPROFEN; HYALURONIC ACID; HYDROGEN SULFIDE; IBUPROFEN; INDOMETACIN; KETOROLAC; KETOROLAC TROMETAMOL; MELOXICAM; NAPROXCINOD; NAPROXEN; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PROSTAGLANDIN SYNTHASE; SI 613; TIFORBEX; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANALGESIA; ARTICLE; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; OSTEOARTHRITIS; PARTICLE SIZE; PERIOPERATIVE PERIOD; STOMACH PROTECTION;

CYCLOOXYGENASE-INHIBITING NITRIC OXIDE DONOR; GLYCOSCIENCE; NANO-FORMULATED; NSAID; SI-613;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; HYALURONIC ACID; HYDROGEN SULFIDE; IBUPROFEN; INJECTIONS; INJECTIONS, INTRA-ARTICULAR; ISOXAZOLES; NANOPARTICLES; NAPROXEN; NITRIC OXIDE DONORS; VASODILATOR AGENTS;

EID: 84890865448     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12278     Document Type: Article

References (48)

1. Richy F, Bruyere O, Ethgen O, etal. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: A consensus statement using a meta-analytic approach. Ann Rheum Dis 2004;63:759-766.
2. Castellsague J, Riera-Guardia N, Calingaert B, etal. Individual NSAIDs and upper gastrointestinal complications: A systematic review and meta-analysis of observational studies (the SOS Project). Drug Saf 2012;35(12):1127-1146.
3. Coxib and Traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet 2013;382(9894):769-779.
4. Rostom A, Dube C, Wells G, etal. The prevention of chronic NSAID-induced gastroduodenal toxicity: A Cochrane collaboration metaanaylsis of randomized controlled trials. J Rheumatol 2000;27(9):2203-2214.
5. Fagerholm U, Breuer O, Swedmark S, etal. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. J Pharm Pharmacol 2005;57:587-597.
6. Muscara M, Wallace J. Nitric oxide. V. Therapeutic potential of nitric oxide donors and inhibitors. Am J Physiol 1999;276:G1213-1216.
7. Karlsson J, Pivodic A, Aguirre D, etal. Efficacy, safety, tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip of knee. J Rheumatol 2009;36(6):1290-1297.
8. Fagerholm U, Bjornsson M. Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. J Pharm Pharmacol 2005;57:1539-1554.
9. Spaulding J, etal. Naproxcinod FDA: Efficacy and Safety Review. Published May 12, 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM212679.pdf (accessed August 27, 2013).
10. Schnitzer T, Hochberg M, Marrero C, etal. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: A 53-week prospective randomized multicenter study. Semin Arthritis Rheum 2011;40:285-297.
11. Schnitzer T, Kivitz A, Frayssinet H, etal. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: A 13-week prospective, randomized, multicenter study. Osteoarthritis Cartilage 2010;18:629-639.
12. Baerwald C, Verdecchia P, Duquesroix B, etal. Efficacy, safety, and effects of blood pressure of naproxcinod 750mg twice daily compared with placebo and naproxen 500mg twice daily in patients with osteoarthritis of the hip. Arthritis Rheum 2010;62(12):3635-3644.
13. White W, Schnitzer T, Bakris G, etal. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol 2011;107:1338-1345.
14. Nicox SA. Nicox today announced promising pre-clinical results on naproxcinod, a CINOD (cyclooxygenase-inhibiting nitric oxide-donating) anti-inflammatory candidate, in models of muscular dystrophies. Published April 23, 2013. Available at: http://www.nicox.com/index.php/en/news-media/news/news-detail/ppreclinical-results-on-naproxcinod-in-models-of-muscular-dystrophy-presented-at-mda-scientific-conferencep (accessed August 25, 2013).
15. Fiorucci S, Distrutti E, Cirino G, etal. The emerging roles of hydrogen sulfide in the gastrontestinal tract and liver. Gastroenterology 2006;131(1):259-272.
16. Szabó C. Hydrogen sulfide and its therapeutic potential. Nat Rev Drug Discov 2007;6(11):917-935.
17. Fiorucci S, Santucci L. Hydrogen sulfide-based therapies: Focus on H2S releasing NSAIDs. Inflamm Allergy Drug Targets 2011;10:133-140.
18. Wallace J, Caliendo G, Santagada V, etal. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat. Gastroenterology 2007;132(1):261-271.
19. Li L, Rossoni G, Sparatore A, etal. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 2007;42(5):706-719.
20. Antibe Therapeutics Inc. ATB-346: Osteoarthritis. Available at: http://antibethera.com/products/lead-drug-atb-346/ (accessed August 28, 2013).
21. Caliendo G, Cirino G, Santagada V, etal. Synthesis and biological effects of hydrogen-sulfide (H2S): Development of H2S-releasing drugs as pharmaceuticals. J Med Chem 2010;53:6275-6286.
22. DailyMed. [Package Insert] ketorolac tromethamine injection, solution. Updated January, 2006. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0336606-7366-41ce-9cef-aa6524b92b11 (accessed September 21, 2013).
23. Drugs@FDA. [Package Insert] Caldolor injection. Published June 11, 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022348lbl.pdf (accessed September 21, 2013).
24. Pavliv L, Voss B, Rock A. Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. Am J Health Syst Pharm 2009;68:47-51.
25. Laska E, Sunshine A, Marrero I, etal. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther 1986;40:1-7.
26. Southworth S, Peters J, Rock A, etal. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400mg and 800mg every 6 hours in the management of postoperative pain. Clin Ther 2011;31(9):1922-1935.
27. Singla N, Rock A, Pavliv LA. Multi-center, randomized, double-blind placebo-controlled trial of intravenous-ibuprofen (IV-ibuprofen) for treatment of pain in post-operative orthopedic adult patients. Pain Med 2010;11:1284-1293.
28. Kroll P, Meadows L, Rock A, etal. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (IV-ibuprofen) in the management of postoperative pain following abdominal hysterectomy. Pain Pract 2011;11(1):23-32.
29. Pizzi L, Toner R, Foley K, etal. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy 2012;32(6):502-514.
30. UK Medicines Information Pharmacists Group. New Medicines on the Market. Parecoxib. Available at: http://www.ukmi.nhs.uk/NewMaterial/html/docs/Parecoxib.pdf (accessed September 4, 2013).
31. Noveck RJ, Hubbard RC. Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters. J Clin Pharmacol 2004;44(5):474-480.
32. Ozgocmen S, Ardicoglu O, Erdogan H, etal. In vivo effects of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci 2005;35(2):137-143.
33. Tenoxicam [package insert]. Takapuna, Aukland, New Zealand: AFT Pharmaceuticals Ltd; 2011. Available at: http://www.medsafe.govt.nz/profs/datasheet/t/tenoxicaminj.pdf (accessed October 30, 2013).
34. Kocaayan E, Ozkardesier S, Ozzeybek D, etal. Comparison of effects of preoperatively administered lornoxicam and tenoxicam on morphine consumption after laparoscopic cholecystectomy. Eur J Anaesthesiol 2007;24(8):714-719.
35. Arsian H, Topcuoglu HS, Aladag H. Effectiveness of tenoxicam and ibuprofen for pain prevention following endodontic therapy in comparison to placebo: A randomized double-blind clinical trial. J Oral Sci 2011;53(2):157-161.
36. Zhang W, Nuki G, Moskowitz R, etal. OARSI recommendations for the management of hip and knee osteoarthritis Part III: Changes in evidence following systematic cumulative update of research published through. Osteoarthritis Cartilage January 2009;18:476-499.
37. SI-613. Seikagaku Corporation: Company Profile. Available at: http://www.seikagaku.co.jp/english/corporate/quicktour/index.html (accessed September 15, 2013).
38. Petersen B, Rovati S. Diclofenac epolamine (Flector®) patch evidence for topical activity. Clin Drug Investig 2009;29(1):1-9.
39. Manvelian G, Daniels S, Altman R. A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated lower-dose oral indomethacin. Postgrad Med 2012;124(4):197-205.
40. Manvelian G, Daniels S, Gibofsky A. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower dose oral diclofenac. Postgrad Med 2012;124(1):117-124.
41. Edgar Online: IPO Alerts. Company Profile: Iroko Pharmaceuticals Inc. Available at: http://ipoalerts.edgar-online.com/ipo/textSection.asp?cikid=909043&fnid=72836&IPO=1&sec=bd&coname=IROKO+PHARMACEUTICALS+INC (accessed September 13, 2013).
42. Argoff C, Nalamachu S, Webster L, etal. Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in phase 3 study in patients following bunionectomy surgery. Osteoarthritis Cartilage 2013;21:S291.
43. Argoff C, Nalamachu S, Webster L, etal. Diclofenac Submicron Particle Capsules Reduce Opioid Rescue Medication Use in a Phase 3 Study in Patients with Acute Pain Following Elective Surgery. PAINWeek Annual Meeting. 2013; Las Vegas, NV.
44. Gibofsky A, Hochberg M, Young CA. Phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis. Osteoarthritis Cartilage 2013;21:S267.
45. Altman R, Saag K, Daniels S, etal. Lower-dose indomethacin submicron particle capsules provide effective acute pain relief: Phase 3 study results. Osteoarthritis Cartilage 2013;21:S267-268.
46. Altman R, etal. Lower-Dose, Indomethacin Submicron Particle Capsules Demonstrate Effective Analgesia in a Phase 3 Post-Surgical Moderate to Severe Pain Model Study. ACR/ARHP Annual Scientific Meeting 2011; Chicago, IL.
47. Lewis S, Langman M, Laporte J, etal. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: A meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54(3):320-326.
48. Vogt M, Fedutes-Henderson B, Duggal A, etal. NSAID usage: Impact of safety data and product withdrawals on prescribing trends. Pharm Ther 2007;32(7):284-287.